New obesity drug combo shows promise in early trial
NCT ID NCT04969939
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding an experimental drug (NNC0165-1875) to the weight-loss medication semaglutide helps people with obesity lose more weight. 120 adults with a BMI between 30 and 45 took part. Participants received either the drug combo or semaglutide plus a placebo, with two injections per week. The study lasted about 26 weeks and looked at safety and weight change.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NNC0165-1875 (an experimental drug) added to semaglutide
- What this could lead to
- If it works, this could lead to a more effective weight-loss treatment for people with obesity.
- What could go wrong
- This is a small, early-phase trial (phase 2) with only 120 participants. The drug combination may not prove safe or effective in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AMC Community Endocrinology
Albany, New York, 12206, United States
-
Accellacare
Wilmington, North Carolina, 28401, United States
-
Altasciences Clinical Kansas, Inc.
Overland Park, Kansas, 66212, United States
-
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
-
Chrysalis Clinical Research
St. George, Utah, 84790, United States
-
Coastal Carolina Res Ctr.
North Charleston, South Carolina, 29405, United States
-
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
-
East West Med Res Inst
Honolulu, Hawaii, 96814, United States
-
Endo Res Solutions Inc
Roswell, Georgia, 30076, United States
-
Evanston Premier Hlthcr Res
Skokie, Illinois, 60077, United States
-
Health Res of Hampton Roads
Newport News, Virginia, 23606, United States
-
Jacksonville Ctr For Clin Res
Jacksonville, Florida, 32216, United States
-
L-MARC Research Center
Louisville, Kentucky, 40213, United States
-
Medical Uni of SC Charleston
Charleston, South Carolina, 29425, United States
-
NYC Research, Inc.
New York, New York, 10016, United States
-
National Clin Res Inc.
Richmond, Virginia, 23294, United States
-
PharmQuest Life Sciences LLC
Greensboro, North Carolina, 27408, United States
-
Profil Institute For Clinical Research Inc
Chula Vista, California, 91911, United States
-
Selma Medical Associates
Winchester, Virginia, 22601-3834, United States
-
Soltero Cardiovascular Research Center
Dallas, Texas, 75226, United States
-
Texas Diabetes & Endocrinology, P.A._Austin
Austin, Texas, 78749, United States
-
Texas Diabetes & Endocrinology, P.A._Austin
Round Rock, Texas, 78681, United States
-
Univ of Alabama Birmingham
Birmingham, Alabama, 35294, United States
-
Velocity Clin Res Los Angeles
Los Angeles, California, 90017, United States
-
Washington Cntr Weight Mgmt
Arlington, Virginia, 22206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?